ストックスクリーナーアプリを入手
19.16
2.24%
0.42
アフターアワーズ：
19.20
0.04
+0.21%
前日終値:
$18.74
開ける：
$18.89
24時間の取引高:
1.19M
Relative Volume:
1.45
時価総額：
$1.10B
収益：
-
当期純損益:
$-100.44M
株価収益率:
-8.6306
EPS:
-2.22
ネットキャッシュフロー:
$-105.32M
1週間 パフォーマンス:
+17.47%
1か月 パフォーマンス:
+0.79%
6か月 パフォーマンス:
-21.38%
1年 パフォーマンス:
-44.17%
1日の値動き範囲:
$18.65
$19.46
1週間の範囲:
$15.85
$19.46
52週間の値動き範囲:
$13.22
$45.37
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
名前
Structure Therapeutics Inc Adr
セクター
電話
(628) 229-9277
住所
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
GPCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
19.16 | 1.08B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-02 | 開始されました | Citigroup | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | Stifel | Buy |
| 2024-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-21 | 開始されました | JP Morgan | Overweight |
| 2024-04-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-07-27 | 開始されました | Piper Sandler | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | BMO Capital Markets | Outperform |
| 2023-02-28 | 開始されました | Guggenheim | Buy |
| 2023-02-28 | 開始されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | SVB Securities | Outperform |
すべてを表示
Structure Therapeutics Inc Adr (GPCR) 最新ニュース
Can Structure Therapeutics’ (GPCR) Aggressive Funding Moves Accelerate Its Obesity Drug Ambitions? - Yahoo Finance
ABSSSI Pipeline 2025: Detailed Clinical Trials - openPR.com
Up 23% to 132%, There's Still Time to Buy These 3 Stocks - The Globe and Mail
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan
FY2025 EPS Estimates for GPCR Lowered by Cantor Fitzgerald - Defense World
William Blair Has Bearish Forecast for GPCR Q3 Earnings - Defense World
FY2025 EPS Estimates for GPCR Decreased by HC Wainwright - Defense World
Leerink Partnrs Has Negative Forecast for GPCR Q3 Earnings - Defense World
Leerink Partnrs Issues Negative Outlook for GPCR Earnings - Defense World
PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating - TipRanks
Why Is Everyone Talking About UnitedHealth Group Stock? - The Globe and Mail
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - AOL.com
Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks
High demand expected for new daily weight loss pill - inkl
Structure Therapeutics (GPCR) to Release Quarterly Earnings on Thursday - Defense World
Structure Therapeutics Reports Q2 2025 Financial Results - TipRanks
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - The Manila Times
The GLP-1 Arms Race: Emerging Innovators and Capital Efficiency in the Obesity Drug Gold Rush - AInvest
Structure Therapeutics Inc ADR (GPCR) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Layoff Tracker: Sirona Liquidates TFChem, Merck Will Cut 6,000 Employees - BioSpace
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Eli Lilly & Co (LLY) and Avantor (AVTR) - The Globe and Mail
2 Beaten-Down Stocks With Incredible Upside Potential - AOL.com
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Eli Lilly & Co (LLY) and Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Chefs’ Warehouse (NASDAQ:CHEF) Reaches New 52-Week High After Better-Than-Expected Earnings - Defense World
Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $76.17 - Defense World
Brookfield (NYSE:BN) Upgraded at National Bank Financial - Defense World
Camden National (NASDAQ:CAC) Stock Price Down 7.6% Following Weak Earnings - Defense World
Century Lithium (OTC:CYDVF) Shares Down 2.6% – What’s Next? - Defense World
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 0.9% – Here’s What Happened - Defense World
HCM Acquisition (NASDAQ:HCMA) Stock Price Down 3.4% – Here’s Why - Defense World
DeFi Technologies (OTC:DEFTF) Trading 20% Higher – What’s Next? - Defense World
GCM Grosvenor (NASDAQ:GCMGW) Trading Up 1.1% – Should You Buy? - Defense World
Encore Capital Group (NASDAQ:ECPG) & Manhattan Bridge Capital (NASDAQ:LOAN) Critical Review - Defense World
Obesity Clinical Trials, Companies, Therapeutic Assessment, - openPR.com
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Viking Therapeutics (VKTX) - The Globe and Mail
Private Advisor Group LLC Buys 489 Shares of Quanta Services, Inc. (NYSE:PWR) - Defense World
Analysts Are Bullish on Top Healthcare Stocks: HOYA (HOCPF), Align Tech (ALGN) - The Globe and Mail
Easterly Investment Partners LLC Has $23.78 Million Stock Position in JPMorgan Chase & Co. (NYSE:JPM) - Defense World
Microchip Technology Incorporated (NASDAQ:MCHP) Holdings Decreased by Private Advisor Group LLC - Defense World
Amazon.com, Inc. (NASDAQ:AMZN) Shares Sold by Shilanski & Associates Inc. - Defense World
Viking Therapeutics Posts Wider Q2 Loss - AOL.com
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - AOL.com
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Sarepta Therapeutics (SRPT) - The Globe and Mail
BMO Nasdaq 100 Equity Hedged to CAD Index ETF (TSE:ZQQ) Trading 0.8% Higher – Time to Buy? - Defense World
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target - Business Wire
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS) - The Globe and Mail
H.C. Wainwright Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Principal Financial Group Inc. Has $14.24 Million Stock Holdings in Universal Display Corporation (NASDAQ:OLED) - Defense World
Principal Financial Group Inc. Decreases Stock Holdings in Shift4 Payments, Inc. (NYSE:FOUR) - Defense World
Principal Financial Group Inc. Sells 11,305 Shares of Nova Ltd. (NASDAQ:NVMI) - Defense World
Structure Therapeutics Inc Adr (GPCR) 財務データ
収益
当期純利益
現金流量
EPS
1.67%
大文字化:
|
ボリューム (24 時間):